Cargando…

Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study

Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease. Our study aimed to assess the outcomes of women with HER2-positive T1a/bN0 breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Sanji, Hendry, Jace, Le, Duc, Mondal, Prosanta K., Sami, Amer, Chalchal, Haji, Haider, Kamal, Ahmed, Osama, El-Gayed, Ali, Wright, Philip, Pauls, Mehrnoosh, Johnson, Kate, Ahmed, Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776836/
https://www.ncbi.nlm.nih.gov/pubmed/35058536
http://dx.doi.org/10.1038/s41598-022-05209-8
_version_ 1784636925390356480
author Ali, Sanji
Hendry, Jace
Le, Duc
Mondal, Prosanta K.
Sami, Amer
Chalchal, Haji
Haider, Kamal
Ahmed, Osama
El-Gayed, Ali
Wright, Philip
Pauls, Mehrnoosh
Johnson, Kate
Ahmed, Shahid
author_facet Ali, Sanji
Hendry, Jace
Le, Duc
Mondal, Prosanta K.
Sami, Amer
Chalchal, Haji
Haider, Kamal
Ahmed, Osama
El-Gayed, Ali
Wright, Philip
Pauls, Mehrnoosh
Johnson, Kate
Ahmed, Shahid
author_sort Ali, Sanji
collection PubMed
description Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease. Our study aimed to assess the outcomes of women with HER2-positive T1a/bN0 breast cancer who received adjuvant trastuzumab in Saskatchewan, Canada. We evaluated all women diagnosed with HER2-positive T1a/bN0 breast cancer in Saskatchewan between 2008 and 2017. We performed Cox proportional multivariable analysis to determine factors correlated with survival. In addition, inverse probability treatment weighting (IPTW) using propensity score was performed to assess benefit of adjuvant trastuzumab. Ninety-one eligible women with a median age of 61 years (range 30–89) were identified. Thirty-nine (43%) women received adjuvant trastuzumab. Women who received trastuzumab were younger and had a higher rate of T1b disease. Overall, 3% of women who received trastuzumab compared to 12% of women who did not receive trastuzumab developed breast cancer recurrence (p = 0.23). Five-year disease-free survival (DFS) of women who received adjuvant trastuzumab was 94.8% compared to 82.7% of women who did not receive trastuzumab (p = 0.22). Five-year overall survival was 100% of women who received trastuzumab compared to 90.4% of women who did not receive adjuvant trastuzumab (p = 0.038). In the multivariable analysis, grade III tumors were correlated with inferior DFS (hazard ratio [HR] 5.5, 95% CI [1.7–17.7]). The propensity score using the inverse probability of treatment weighting showed that lack of adjuvant trastuzumab was correlated inferior DFS, with an HR of 4 (95% CI 1.05–15.5). Women with HER2-positive T1a/bN0 breast cancer had overall low recurrence of breast cancer. However, the results of this exploratory analysis indicate that women who received adjuvant trastuzumab had better survival.
format Online
Article
Text
id pubmed-8776836
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87768362022-01-24 Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study Ali, Sanji Hendry, Jace Le, Duc Mondal, Prosanta K. Sami, Amer Chalchal, Haji Haider, Kamal Ahmed, Osama El-Gayed, Ali Wright, Philip Pauls, Mehrnoosh Johnson, Kate Ahmed, Shahid Sci Rep Article Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease. Our study aimed to assess the outcomes of women with HER2-positive T1a/bN0 breast cancer who received adjuvant trastuzumab in Saskatchewan, Canada. We evaluated all women diagnosed with HER2-positive T1a/bN0 breast cancer in Saskatchewan between 2008 and 2017. We performed Cox proportional multivariable analysis to determine factors correlated with survival. In addition, inverse probability treatment weighting (IPTW) using propensity score was performed to assess benefit of adjuvant trastuzumab. Ninety-one eligible women with a median age of 61 years (range 30–89) were identified. Thirty-nine (43%) women received adjuvant trastuzumab. Women who received trastuzumab were younger and had a higher rate of T1b disease. Overall, 3% of women who received trastuzumab compared to 12% of women who did not receive trastuzumab developed breast cancer recurrence (p = 0.23). Five-year disease-free survival (DFS) of women who received adjuvant trastuzumab was 94.8% compared to 82.7% of women who did not receive trastuzumab (p = 0.22). Five-year overall survival was 100% of women who received trastuzumab compared to 90.4% of women who did not receive adjuvant trastuzumab (p = 0.038). In the multivariable analysis, grade III tumors were correlated with inferior DFS (hazard ratio [HR] 5.5, 95% CI [1.7–17.7]). The propensity score using the inverse probability of treatment weighting showed that lack of adjuvant trastuzumab was correlated inferior DFS, with an HR of 4 (95% CI 1.05–15.5). Women with HER2-positive T1a/bN0 breast cancer had overall low recurrence of breast cancer. However, the results of this exploratory analysis indicate that women who received adjuvant trastuzumab had better survival. Nature Publishing Group UK 2022-01-20 /pmc/articles/PMC8776836/ /pubmed/35058536 http://dx.doi.org/10.1038/s41598-022-05209-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ali, Sanji
Hendry, Jace
Le, Duc
Mondal, Prosanta K.
Sami, Amer
Chalchal, Haji
Haider, Kamal
Ahmed, Osama
El-Gayed, Ali
Wright, Philip
Pauls, Mehrnoosh
Johnson, Kate
Ahmed, Shahid
Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
title Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
title_full Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
title_fullStr Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
title_full_unstemmed Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
title_short Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
title_sort efficacy of adjuvant trastuzumab in women with her2-positive t1a or bn0m0 breast cancer: a population-based cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776836/
https://www.ncbi.nlm.nih.gov/pubmed/35058536
http://dx.doi.org/10.1038/s41598-022-05209-8
work_keys_str_mv AT alisanji efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT hendryjace efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT leduc efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT mondalprosantak efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT samiamer efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT chalchalhaji efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT haiderkamal efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT ahmedosama efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT elgayedali efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT wrightphilip efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT paulsmehrnoosh efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT johnsonkate efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy
AT ahmedshahid efficacyofadjuvanttrastuzumabinwomenwithher2positivet1aorbn0m0breastcancerapopulationbasedcohortstudy